OBJECTIVE: To estimate the prevalence of the metabolic syndrome in the Netherlands in two populations in the age category 28-59 years and to compare this with the prevalence of hypercholesterolaemia in these populations. DESIGN: Descriptive. METHOD: Data from two Dutch population based studies were used: the 'Monitoring risicofactoren en gezondheid Nederland' (MORGEN) study ['Monitoring risk factors and health in the Netherlands' study] (1993-1995) and the 'Prevention of renal and vascular end-stage disease' (PREVEND) study (1998-1999). Subjects were identified as having the metabolic syndrome when they had at least three of the following five criteria according to the guideline of the 'National cholesterol education programme', 'Adult treatment panel III' (NCEP-2001): hyperglycaemia, low HDL-cholesterol level, hypertriglyceridaemia, hypertension or abdominal obesity. Final estimates were weighed according to the age- and sex distribution of the Dutch population during these survey years based on figures of the Dutch Central Bureau of Statistics. RESULTS: On average, the prevalence of the metabolic syndrome was 14%, 19% in men and 12% in women in the MORGEN study, and 16% and 10% in men and women in the PREVEND study. The prevalence in subjects below 40 was 12% for men and 5% for women. The prevalence increased considerably with age. Among subjects with both abdominal obesity and hypertension the prevalence was 68%. Among subjects with 'hypertriglyceridaemic waist' the prevalence was 94%. The prevalence of the metabolic syndrome showed little overlap with the prevalence of hypercholesterolaemia (> or = 6.5 mmol/l). In total, 26% of the subjects had either the metabolic syndrome or high total cholesterol levels. CONCLUSION: Approximately 1 million Dutch adults below 60 years of age had the metabolic syndrome in the 1990's. Based on the total prevalence of the metabolic syndrome and hypercholesterolaemia, one quarter of the Dutch population younger then 60 runs an increased risk of cardiovascular disease and type 2 diabetes mellitus.
OBJECTIVE: To estimate the prevalence of the metabolic syndrome in the Netherlands in two populations in the age category 28-59 years and to compare this with the prevalence of hypercholesterolaemia in these populations. DESIGN: Descriptive. METHOD: Data from two Dutch population based studies were used: the 'Monitoring risicofactoren en gezondheid Nederland' (MORGEN) study ['Monitoring risk factors and health in the Netherlands' study] (1993-1995) and the 'Prevention of renal and vascular end-stage disease' (PREVEND) study (1998-1999). Subjects were identified as having the metabolic syndrome when they had at least three of the following five criteria according to the guideline of the 'National cholesterol education programme', 'Adult treatment panel III' (NCEP-2001): hyperglycaemia, low HDL-cholesterol level, hypertriglyceridaemia, hypertension or abdominal obesity. Final estimates were weighed according to the age- and sex distribution of the Dutch population during these survey years based on figures of the Dutch Central Bureau of Statistics. RESULTS: On average, the prevalence of the metabolic syndrome was 14%, 19% in men and 12% in women in the MORGEN study, and 16% and 10% in men and women in the PREVEND study. The prevalence in subjects below 40 was 12% for men and 5% for women. The prevalence increased considerably with age. Among subjects with both abdominal obesity and hypertension the prevalence was 68%. Among subjects with 'hypertriglyceridaemic waist' the prevalence was 94%. The prevalence of the metabolic syndrome showed little overlap with the prevalence of hypercholesterolaemia (> or = 6.5 mmol/l). In total, 26% of the subjects had either the metabolic syndrome or high total cholesterol levels. CONCLUSION: Approximately 1 million Dutch adults below 60 years of age had the metabolic syndrome in the 1990's. Based on the total prevalence of the metabolic syndrome and hypercholesterolaemia, one quarter of the Dutch population younger then 60 runs an increased risk of cardiovascular disease and type 2 diabetes mellitus.
Authors: Jenny van Dongen; Gonneke Willemsen; Wei-Min Chen; Eco J C de Geus; Dorret I Boomsma Journal: J Lipid Res Date: 2013-08-05 Impact factor: 5.922
Authors: Cécile M Povel; Joline W Beulens; Yvonne T van der Schouw; Martijn E T Dollé; Annemieke M W Spijkerman; W M Monique Verschuren; Edith J M Feskens; Jolanda M A Boer Journal: Diabetes Care Date: 2012-08-29 Impact factor: 19.112
Authors: Sergio Bizzarro; Ubele van der Velden; Wijnand J Teeuw; Victor E A Gerdes; Bruno G Loos Journal: J Clin Periodontol Date: 2017-07-12 Impact factor: 8.728
Authors: Doris M Jacobs; Lotte Smolders; Yuguang Lin; Niels de Roo; Elke A Trautwein; John van Duynhoven; Ronald P Mensink; Jogchum Plat; Velitchka V Mihaleva Journal: Front Mol Biosci Date: 2017-08-24
Authors: Lotte Smolders; Ronald P Mensink; Jose J van den Driessche; Peter J Joris; Jogchum Plat Journal: Eur J Nutr Date: 2018-01-12 Impact factor: 5.614
Authors: Carmen S S Latenstein; Louise J M Alferink; Sarwa Darwish Murad; Joost P H Drenth; Cornelis J H M van Laarhoven; Philip R de Reuver Journal: Clin Transl Gastroenterol Date: 2020-04 Impact factor: 4.396